Answer
RoActemra (tocilizumab) is indicated for patients aged 2 years and older with active systemic juvenile idiopathic arthritis who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs and systemic corticosteroids.
Sources for this answer
- RoActemra 20mg/ml Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 37Document updated
Sources checked